Biotechnology

Chris Smith, analyst - Japanese equities at Polar Capital, discusses the evolution of the Japanese market and the search for income.

Overuse of antibiotics around the globe has created a worrying increase in resistance to many commonly used drugs, writes Carl Harald Janson, lead manager on the International Biotechnology trust.

With all three rating agencies lowering growth expectations for the domestic economy following the referendum result last month, the attractions of investing for long-term growth in the technology related sectors has again been highlighted in our view....

Trump and Clinton fight for presidency

Founding partner of Sloane Robinson

Healthcare was one sector that did not fully participate in the recent stockmarket rally and finished the first quarter as the worst performer in the S&P 500 index, writes Legg Mason's Evan Bauman.

Shares dropped 90% since summer

The pharmaceutical and biotechnology sector has performed well in recent years, primarily by virtue of attractive fundamentals.

Gold funds top performance charts

Biotech has fallen